PMID- 32449002
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20200915
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 146
IP  - 10
DP  - 2020 Oct
TI  - The effect of proton pump inhibitors on survival outcomes in advanced 
      hepatocellular carcinoma treated with sorafenib.
PG  - 2693-2697
LID - 10.1007/s00432-020-03261-3 [doi]
AB  - PURPOSE: Sorafenib is an oral tyrosine kinase inhibitor (TKI) and first-line 
      treatment option for advanced hepatocellular carcinoma (HCC). Preliminary 
      evidence indicates proton pump inhibitors (PPI) may affect the absorption of TKIs 
      through decreased gut dissolution. This study aims to evaluate the impact of PPI 
      use on the survival outcomes of advanced HCC patients treated with sorafenib. 
      METHODS: The study was a secondary analysis of individual-participant data from 
      the phase III clinical trial NCT00699374. Cox proportional hazard analysis was 
      used to evaluate the association between baseline PPI use and survival outcomes. 
      Overall survival (OS) was the primary outcome with progression-free survival 
      (PFS) secondary. RESULTS: In a cohort of 542 advanced HCC patients initiating 
      sorafenib treatment, 122 were concomitantly using a PPI at baseline. No 
      significant associations between baseline PPI use and OS were identified on 
      univariable (HR [95% CI]; 1.01 [0.80-1.28], P = 0.93) and adjusted (1.10 
      [0.82-1.41], P = 0.62) analysis. Furthermore, no significant associations between 
      baseline PPI use and PFS were identified on univariable (0.96 [0.76-1.21], 
      P = 0.73) and adjusted (1.11 [0.86-1.44], P = 0.41) analysis. CONCLUSION: In a 
      large high-quality dataset, PPI use was not observed to compromise the survival 
      outcomes of advanced HCC patients initiated on sorafenib.
FAU - Ruanglertboon, Warit
AU  - Ruanglertboon W
AUID- ORCID: 0000-0003-0540-7427
AD  - Department of Clinical Pharmacology, College of Medicine and Public Health, 
      Flinders University, Adelaide, Australia. warit.ruanglertboon@flinders.edu.au.
FAU - Sorich, Michael J
AU  - Sorich MJ
AD  - Department of Clinical Pharmacology, College of Medicine and Public Health, 
      Flinders University, Adelaide, Australia.
FAU - Logan, Jessica M
AU  - Logan JM
AD  - Mechanisms in Cell Biology and Disease Research Group, Clinical and Health 
      Sciences, Cancer Research Institute, University of South Australia, Adelaide, 
      Australia.
FAU - Rowland, Andrew
AU  - Rowland A
AD  - Department of Clinical Pharmacology, College of Medicine and Public Health, 
      Flinders University, Adelaide, Australia.
FAU - Hopkins, Ashley M
AU  - Hopkins AM
AD  - Department of Clinical Pharmacology, College of Medicine and Public Health, 
      Flinders University, Adelaide, Australia.
LA  - eng
GR  - 1127220/Cancer Council South Australia/
GR  - 1159924/Cancer Council South Australia/
GR  - PF-17-007/National Breast Cancer Foundation (AUS)/
PT  - Journal Article
DEP - 20200524
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Carcinoma, Hepatocellular/*drug therapy/*metabolism/mortality
MH  - Clinical Trials, Phase III as Topic
MH  - Cohort Studies
MH  - Drug Synergism
MH  - Gastrointestinal Absorption/drug effects
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/*drug therapy/*metabolism/mortality
MH  - Progression-Free Survival
MH  - Proportional Hazards Models
MH  - Protein Kinase Inhibitors/pharmacokinetics/therapeutic use
MH  - Proton Pump Inhibitors/*administration & dosage/*pharmacology
MH  - Sorafenib/*administration & dosage/*pharmacokinetics
MH  - Survival Rate
OTO - NOTNLM
OT  - Prediction
OT  - Proton pump inhibitors
OT  - Sorafenib
OT  - Survival outcomes
EDAT- 2020/05/26 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - 10.1007/s00432-020-03261-3 [pii]
AID - 10.1007/s00432-020-03261-3 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2020 Oct;146(10):2693-2697. doi: 
      10.1007/s00432-020-03261-3. Epub 2020 May 24.